Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

Income Statement
Quarterly Data

Pfizer Inc., consolidated income statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Product revenues 15,083 15,418 10,871 12,444 12,338 11,587 10,767 16,222
Alliance revenues 2,249 1,900 2,067 2,172 1,910 1,645 1,967 2,060
Royalty revenues 431 384 345 263 320 260 273 204
Revenues (legacy) 24,289 22,638 27,742 25,661 23,838 24,035 18,899 14,516 11,684 10,277 9,864 10,083
Revenues 17,763 17,702 13,283 14,879 14,568 13,492 13,007 18,486 24,289 22,638 27,742 25,661 23,838 24,035 18,899 14,516 11,684 10,277 9,864 10,083
Cost of sales (5,909) (5,263) (3,300) (3,379) (7,562) (9,269) (3,237) (4,886) (9,649) (6,063) (8,648) (9,984) (9,736) (9,932) (6,996) (4,157) (2,919) (2,007) (1,826) (1,940)
Gross profit 11,854 12,439 9,983 11,500 7,006 4,223 9,770 13,600 14,640 16,575 19,094 15,677 14,102 14,103 11,903 10,359 8,765 8,270 8,038 8,143
Selling, informational and administrative expenses (4,274) (3,244) (3,717) (3,495) (4,575) (3,281) (3,497) (3,418) (4,645) (3,391) (3,048) (2,593) (4,104) (2,899) (2,923) (2,777) (3,757) (2,658) (2,659) (2,541)
Research and development expenses (3,035) (2,598) (2,696) (2,493) (2,815) (2,711) (2,648) (2,505) (3,616) (2,696) (2,815) (2,301) (3,446) (2,681) (2,239) (1,994) (3,355) (2,300) (2,078) (1,672)
Acquired in-process research and development expenses (89) (13) (6) (73) (67) (33) (21) (73) (524) (1) (355) (2,469) (762) (219) (19)
Amortization of intangible assets (1,359) (1,312) (1,307) (1,308) (1,267) (1,179) (1,184) (1,103) (1,130) (822) (822) (835) (957) (968) (917) (858) (856) (862) (869) (849)
Restructuring charges and certain acquisition-related costs (750) (313) (1,254) (102) (2,565) (155) (214) (9) (795) (199) (189) (192) (135) (646) 1 (22) (184) (2) (360) (54)
Operating income (loss) 2,347 4,959 1,003 4,102 (4,289) (3,170) 2,194 6,544 4,381 8,943 12,219 9,401 2,991 6,147 5,606 4,689 613 2,448 2,072 3,027
Gain on completion of Consumer Healthcare JV transaction 6
Other income (deductions), net (2,357) (244) (1,106) (681) 160 (182) 75 (274) 849 58 (772) (350) 836 1,696 1,342 1,004 446 (1,878) 954 (191)
Income (loss) from continuing operations before (provision) benefit for taxes on income (loss) (10) 4,715 (103) 3,421 (4,129) (3,352) 2,269 6,270 5,230 9,001 11,447 9,051 3,827 7,843 6,948 5,693 1,059 570 3,026 2,842
(Provision) benefit for taxes on income (loss) 421 (234) 134 (293) 794 964 71 (715) (230) (356) (1,570) (1,172) (249) 328 (1,123) (808) (42) 347 (422) (359)
Income (loss) from continuing operations 411 4,481 31 3,128 (3,335) (2,388) 2,340 5,555 5,000 8,645 9,877 7,879 3,578 8,171 5,825 4,885 1,017 917 2,604 2,483
Discontinued operations, net of tax 7 (8) 17 (5) (25) 12 (2) 1 3 (22) 34 (9) (187) (12) (236) 1 297 560 893 881
Net income (loss) before allocation to noncontrolling interests 418 4,473 48 3,123 (3,360) (2,376) 2,338 5,556 5,003 8,623 9,911 7,870 3,391 8,159 5,589 4,886 1,314 1,477 3,497 3,364
Net income attributable to noncontrolling interests (8) (8) (7) (8) (9) (6) (11) (13) (9) (15) (5) (6) 2 (13) (26) (9) (11) (8) (8) (9)
Net income (loss) attributable to Pfizer Inc. common shareholders 410 4,465 41 3,115 (3,369) (2,382) 2,327 5,543 4,994 8,608 9,906 7,864 3,393 8,146 5,563 4,877 1,303 1,469 3,489 3,355

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

Income statement item Description The company
Revenues Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Pfizer Inc. revenues increased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.
Operating income (loss) The net result for the period of deducting operating expenses from operating revenues. Pfizer Inc. operating income (loss) increased from Q2 2024 to Q3 2024 but then slightly decreased from Q3 2024 to Q4 2024 not reaching Q2 2024 level.
Income (loss) from continuing operations before (provision) benefit for taxes on income (loss) Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Pfizer Inc. income (loss) from continuing operations before (provision) benefit for taxes on income (loss) increased from Q2 2024 to Q3 2024 but then slightly decreased from Q3 2024 to Q4 2024 not reaching Q2 2024 level.
Net income (loss) attributable to Pfizer Inc. common shareholders The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Pfizer Inc. net income (loss) attributable to Pfizer Inc. common shareholders increased from Q2 2024 to Q3 2024 but then slightly decreased from Q3 2024 to Q4 2024 not reaching Q2 2024 level.